Acumen Pharmaceuticals, Inc
Acumen Pharmaceuticals is dedicated to developing targeted therapies for Alzheimer's disease, focusing on building upon current momentum to improve patient outcomes. Their mission is to develop treatments that help patients hold on to their moments and create new ones, emphasizing the importance of moments in life. The company is focused on advancing treatment options for Alzheimer's by targeting toxic soluble amyloid beta oligomers (AβOs), which are primary drivers of neurodegeneration in Alzheimer's disease.
Industries
Nr. of Employees
small (1-50)
Acumen Pharmaceuticals, Inc
Carmel, Indiana, United States, North America
Patents
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
US-9320793-B2
View DetailsADDL receptor polypeptides, polynucleotides and host cells for recombinant production
US-9217024-B2
View DetailsMonoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
US-8507206-B2
View DetailsCompositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance
US-7964359-B2
View Details
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
US-9320793-B2
View DetailsADDL receptor polypeptides, polynucleotides and host cells for recombinant production
US-9217024-B2
View DetailsMonoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
US-8507206-B2
View DetailsCompositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance
US-7964359-B2
View DetailsProducts
ACU193
A monoclonal antibody targeting toxic soluble amyloid-beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
INTERCEPT-AD Trial
A Phase 1 clinical trial for ACU193, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
ACU193
A monoclonal antibody targeting toxic soluble amyloid-beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
INTERCEPT-AD Trial
A Phase 1 clinical trial for ACU193, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
News & Updates
A recruitment poster for the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.
A poster related to pharmacokinetics at the 2023 CTAD conference.
Another pharmacokinetics poster presented at the 2023 CTAD conference.
A recruitment poster for the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.
A poster related to pharmacokinetics at the 2023 CTAD conference.
Another pharmacokinetics poster presented at the 2023 CTAD conference.